Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- VCU Massey Cancer Center at Hanover Medical Park — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Virginia: - Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia
- VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- VCU Health Tappahannock Hospital — Tappahannock, Virginia
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- Virginia Commonwealth University/Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Virginia: - University of Virginia Health System ( Site 0054) — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 0061) — Richmond, Virginia
- Blue Ridge Cancer Care ( Site 0004) — Roanoke, Virginia
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Virginia: - Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Virginia Cancer Specialists PC — Leesburg, Virginia
- Bon Secours Cancer Institute at Saint Francis — Midlothian, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Virginia: - Virginia Oncology Associates — Norfolk, Virginia
- Blue Ridge Cancer Center — Wytheville, Virginia
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
- Onco Hemato Asso of SW Virginia — Roanoke, Virginia
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Virginia: - Hunter Holmes McGuire VA Medical Center, Richmond, VA — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Virginia: - Urology of Virginia — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Virginia: - Research Site 102 — Fairfax, Virginia
- Research Site 112 — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Virginia: - Emily Couric Clinical Cancer Center — Charlottesville, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Virginia: - University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Virginia: - Virginia Clinical Research — Norfolk, Virginia
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Virginia: - NEXT, Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07730021
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostat…
Sponsor: University of Virginia
NCT ID: NCT07441889
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Virginia: - Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 1 Recruiting Industry
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…
Sponsor: Amgen
NCT ID: NCT04221542
Sites in Virginia: - Virginia Cancer Specialists PC — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia